MONDAY, Dec. 23, 2024 (HealthDay News) — The U.S. Food and Drug Administration (FDA) has approved the first prescription medication specifically for treating obstructive sleep apnea (OSA): the weight-loss drug Zepbound. In a news release published Dec. 20, the FDA stated that Zepbound, part of the GLP-1 receptor agonist medicinesContinue Reading
THURSDAY, Dec. 19, 2024 (HealthDay News) — The U.S. Food and Drug Administration re-issued a decision first made by the agency in October that a shortage of the diabetes/weight-loss medication tirzepatide is over. Tirzepatide includes blockbuster injected GLP-1 medications Mounjaro (for diabetes) and Zepbound (for weight loss). The FDA firstContinue Reading
FRIDAY, Dec. 13, 2024 (HealthDay News) — The U.S. obesity rate declined for the first time in a decade last year, coinciding with the rise of GLP-1 weight-loss meds, a new study finds. Data on almost 17 million adults nationwide showed the obesity rate — which has been rising forContinue Reading
THURSDAY, Dec. 12, 2024 (HealthDay News) — Unhealthy ultra-processed foods have wormed their way into American kitchens, likely harming people’s health for decades, a new study warns. More than half of the calories adults eat at home now come from ultra-processed foods, which contain high levels of sugar, salt, fatContinue Reading
TUESDAY, Dec. 10, 2024 (HealthDay News) — People with diabetes who are taking GLP-1 meds such as Ozempic or Mounjaro may be getting an added bonus: Reductions in their odds for a dangerous blood clot, new research finds. The study found that folks with diabetes who were using the drugsContinue Reading
FRIDAY, Dec. 6, 2024 (HealthDay News) — Americans are falling farther behind the rest of the developed world when it comes to health and life expectancy, a new study shows. Life expectancy in the United States is expected to increase to 79.9 years in 2035 and 80.4 years by 2050,Continue Reading
FRIDAY, Dec. 6, 2024 (HealthDay News) — Eating lots of ultra-processed foods appears linked to a buildup of fat in the thighs, which in turn raises a person’s odds for arthritis in the knees, new research shows. “In an adult population at risk for but without knee or hip osteoarthritis,Continue Reading
THURSDAY, Dec. 5, 2024 (HealthDay News) — The advent of GLP-1 weight-loss medications such as Wegovy and Zepbound has spurred debate as to whether the drugs’ cost should be covered by Medicare, Medicaid and private insurers. Late last month, the Biden administration proposed that the drugs be covered by MedicareContinue Reading
THURSDAY, Dec. 5, 2024 (HealthDay News) — Fatty liver disease may contribute to fragmented sleep patterns, robbing already sick people of good rest, a new study finds. These folks woke up more often in the night, and then lay awake longer waiting for slumber to reclaim them, researchers found. TheseContinue Reading
WEDNESDAY, Dec. 4, 2024 (HealthDay News) — Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly. “Given the increased interest around obesity medications, we conducted this study to help health care providers and patients makeContinue Reading
TUESDAY, Dec. 3, 2024 (HealthDay News) — GLP-1 meds are all the rage for weight loss nowadays, but not everyone can safely take the drugs to shed pounds. Invasive weight-loss surgeries can often be a tough sell, too. Now, researchers at the Massachusetts Institute of Technology (MIT) say they’ve developedContinue Reading
TUESDAY, Dec. 3, 2024 (HealthDay News) — An accumulation of fat lurking around the organs of obese people is strongly linked to a buildup of Alzheimer’s-linked proteins in the brain, new research finds. Buildup of this visceral fat in middle age may boost levels of the two damaging brain proteins,Continue Reading
WEDNESDAY, Nov. 27, 2024 (HealthDay News) — The cutting-edge weight-loss drug Zepbound can protect obese people from developing type 2 diabetes, a new clinical trial has found. Zepbound reduced the risk of diabetes in obese prediabetic patients by more than 90% during a three-year period compared to placebo, trial resultsContinue Reading
TUESDAY, Nov. 26, 2024 (HealthDay News) — The outgoing Biden administration will propose that pricey GLP-1 obesity medications such as semaglutide (Wegovy), and tirzepatide (Zepbound) be covered by Medicare and Medicaid. However, the move would have to be approved by the new Trump administration. Right now, a law passed byContinue Reading